Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) Tax Provisions (2019 - 2025)

Neurocrine Biosciences' Tax Provisions history spans 7 years, with the latest figure at $85.7 million for Q4 2025.

  • For Q4 2025, Tax Provisions rose 44.03% year-over-year to $85.7 million; the TTM value through Dec 2025 reached $226.8 million, up 56.74%, while the annual FY2025 figure was $226.8 million, 56.74% up from the prior year.
  • Tax Provisions reached $85.7 million in Q4 2025 per NBIX's latest filing, up from $82.3 million in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $85.7 million in Q4 2025 to a low of -$26.7 million in Q1 2023.
  • Average Tax Provisions over 5 years is $26.3 million, with a median of $27.5 million recorded in 2022.
  • Peak YoY movement for Tax Provisions: surged 1500.0% in 2021, then tumbled 456.0% in 2023.
  • A 5-year view of Tax Provisions shows it stood at -$6.5 million in 2021, then skyrocketed by 544.62% to $28.9 million in 2022, then surged by 74.74% to $50.5 million in 2023, then rose by 17.82% to $59.5 million in 2024, then soared by 44.03% to $85.7 million in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Tax Provisions are $85.7 million (Q4 2025), $82.3 million (Q3 2025), and $52.0 million (Q2 2025).